In another embodiment, the invention provides to be used to screen and be the candidate of the substrate of treatment target of the present invention or its biologically-active moiety or the algoscopy of test compounds.In another embodiment, the invention provides to be used to screen and combine treatment target of the present invention or the candidate of its biologically-active moiety or the algoscopy of test compounds.Measure the ability of the direct combined treatment target of test compounds can be for example through said chemical compound and radiosiotope or enzymatic labelling coupling (so that chemical compound and medicine target combine and can measure through the labelled compound of labelling in the detection complex) are realized.For example, can use directly or indirectly 131 I, 125 I, 35 S, 14 C or 3 H labelled compound (for example, labeled substrate), and through the direct count of radio radiation (radioemission) or through scinticounting detection of radioactive isotope.Selectively, available for example horseradish peroxidase, alkali phosphatase or luciferase enzymatic labelling are measured composition, and detect said enzymatic labelling through measuring being converted of suitable substrate to product
Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent
[DOI] [Google Scholar] 27.Amany M.M.B., Shaker M.A., Abeer A.K
mansoni : plerocercoid stage and adult stage (including immature proglottide, mature proglottide and gravid proglottide)
